270 related articles for article (PubMed ID: 16084177)
1. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer.
Zeliadt SB; Etzioni RD; Penson DF; Thompson IM; Ramsey SD
Am J Med; 2005 Aug; 118(8):850-7. PubMed ID: 16084177
[TBL] [Abstract][Full Text] [Related]
2. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
5. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?
Grover S; Lowensteyn I; Hajek D; Trachtenberg J; Coupal L; Marchand S
J Urol; 2006 Mar; 175(3 Pt 1):934-8; discussion 938. PubMed ID: 16469585
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
McDonald H; Hux M; Brisson M; Bernard L; Nickel JC
Can J Urol; 2004 Aug; 11(4):2327-40. PubMed ID: 15380054
[TBL] [Abstract][Full Text] [Related]
7. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
[TBL] [Abstract][Full Text] [Related]
8. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial.
Cohen YC; Liu KS; Heyden NL; Carides AD; Anderson KM; Daifotis AG; Gann PH
J Natl Cancer Inst; 2007 Sep; 99(18):1366-74. PubMed ID: 17848668
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of cataract surgery in the second eye.
Busbee BG; Brown MM; Brown GC; Sharma S
Ophthalmology; 2003 Dec; 110(12):2310-7. PubMed ID: 14644712
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of sevelamer in patients with end-stage renal disease.
Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
[TBL] [Abstract][Full Text] [Related]
12. A value-based medicine cost-utility analysis of idiopathic epiretinal membrane surgery.
Gupta OP; Brown GC; Brown MM
Am J Ophthalmol; 2008 May; 145(5):923-8. PubMed ID: 18329000
[TBL] [Abstract][Full Text] [Related]
13. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
Rein DB; Wittenborn JS; Lee PP; Wirth KE; Sorensen SW; Hoerger TJ; Saaddine JB
Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
[TBL] [Abstract][Full Text] [Related]
14. A cost--utility analysis of treatment options for inguinal hernia in 1,513,008 adult patients.
Stylopoulos N; Gazelle GS; Rattner DW
Surg Endosc; 2003 Feb; 17(2):180-9. PubMed ID: 12415334
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
17. Can hip protector use cost-effectively prevent fractures in community-dwelling geriatric populations?
Honkanen LA; Mushlin AI; Lachs M; Schackman BR
J Am Geriatr Soc; 2006 Nov; 54(11):1658-65. PubMed ID: 17087691
[TBL] [Abstract][Full Text] [Related]
18. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of dual-chamber pacing compared with ventricular pacing for sinus node dysfunction.
Rinfret S; Cohen DJ; Lamas GA; Fleischmann KE; Weinstein MC; Orav J; Schron E; Lee KL; Goldman L
Circulation; 2005 Jan; 111(2):165-72. PubMed ID: 15630030
[TBL] [Abstract][Full Text] [Related]
20. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
